Health Care • Biotechnology: Pharmaceutical Preparations
$2.23 ▼ -0.14
(-5.91%)
MKT CAP: $22.3M • VOL: 68.0K
52W L $2 52W H $15
ROARABLE / RQD
D- • 36/100
PIOTROSKI
2 / 9
ATOS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$37.1M | -$27.6M | -$31.4M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$34.8M | -$25.5M | -$30.1M |
| EBITDA (Normalized) | -$37.1M | -$27.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$29.8M | -$21.0M | -$20.9M |
| Capital Expenditures (CapEx) | $23.0K | $19.0K | — |
| Free Cash Flow (FCF) | -$29.8M | -$21.0M | -$20.9M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $41.3M | $71.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $39.4M | $71.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ATOS.